In PNAS this week: similar muscle protein patterns across hypertrophic cardiomyopathy phenotypes, analysis of gene expression and brain anatomy in major depression, and more.
The trial will use Natera's Signatera test to determine patient enrollment eligibility based on the presence of ctDNA and to evaluate response based on ctDNA clearance.
Accounting for polygenic background in conditions like hereditary breast cancer or Lynch syndrome can increase the accuracy of disease risk estimation.
The technology could be developed into therapies for diseases caused by DNA transversion point mutations, and used to conduct molecular research on such conditions.
Three research teams profiled proteomic, genomic, and other features in lung adenocarcinomas in Asia and other parts of the world, including cases in never-smokers.
Irvine, California-based Fluxergy is working with the MGB Center for COVID Innovation to evaluate the firm's research-use-only COVID-19 testing platform.
